CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting at the J.P. Morgan 2026 Healthcare conference on Wednesday, January 14th at 4:30-5:10 pm PT in San Francisco, CA. During the conference, Carlsmed Management will be hosting 1x1 investor meetings. About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery soluti ...

Key Takeaways CARL has begun U.S. commercialization of its aprevo cervical platform with more than 50 cases completed.CARL's AI-driven planning and 3D-printed implants showed improved alignment and workflow integration.NTAP reimbursement, FDA clearance and clinical milestones strengthened CARL's platform outlook.Carlsmed (CARL) recently announced the U.S. commercial launch of its aprevo Technology Platform for cervical fusion procedures at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting in Wa ...

Carlsmed (NasdaqGS:CARL) FY Conference December 03, 2025 09:00 AM ET Company ParticipantsMike Cordonnier - CEOConference Call ParticipantsMatt O'Brien - AnalystMatt O'BrienGood morning, everybody. Thanks so much for joining us. My name is Matt O'Brien. I'm one of the med tech analysts here at Piper Sandler. Very excited to have Carlsmed here with us, you know, all the way across the country. Thanks for coming. From the company, we have Mike, who is the CEO. Leo, CFO, is back in the audience. Mike, thanks ag ...

First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch WorkshopCARLSBAD, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Technology Platform for cervical fusion surgeries. Surgeons involved in the clinical evaluation will also present early clinical data at the Cervical Spine Research Society (CSRS) 53rd Annual ...

Core Viewpoint - Carlsmed, Inc. is set to present at the 37th Annual Piper Sandler Healthcare conference, highlighting its focus on AI-enabled personalized spine surgery solutions aimed at improving healthcare outcomes and reducing costs [1]. Company Overview - Carlsmed is a medical technology company specializing in AI-enabled personalized spine surgery solutions [3]. - The company's mission is to enhance outcomes and lower healthcare costs associated with spine surgery and related areas [3]. Event Details - Mike Cordonnier, Chairman and CEO of Carlsmed, will present at the conference on December 3rd from 9:00 to 9:25 am ET in New York, NY [1]. - The company will also host one-on-one investor meetings during the conference [1]. - A live webcast of the presentation will be available for registered participants, with a replay accessible afterward [2].

Carlsmed (NasdaqGS:CARL) Q3 2025 Earnings Call November 06, 2025 04:30 PM ET Speaker0Ladies and gentlemen, thank you for standing by, and welcome to the Carlsmed Third Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. I would now like to turn the conference over to your first speaker today, Caroline Corner, Investor Relations. Please go ahead, Caroline.Speaker2Thank you, operator. We ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42756 CARLSMED, INC. (Exact Name of Registrant as Specified in its Charter) ( State or other jurisdiction of incorporation or ...

Exhibit 99.1 Carlsmed®Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., November 6, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30 ...

Third quarter revenue of $13.1 million, representing 98% growth YoY  Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025.  "We delivered another strong quarter with 98% revenue growth year-over-year, expanded gros ...

Core Insights - Carlsmed, Inc. is set to report its third quarter 2025 financial results on November 6, 2025, after market close [1] - A conference call and webcast will be held on the same day at 1:30 PM Pacific Time to discuss the financial results [2] Company Overview - Carlsmed is a medical technology company focused on AI-enabled personalized spine surgery solutions, aiming to enhance healthcare outcomes and reduce costs associated with spine surgery [3]